Sorrento Therapeutics stock plummets more than 60% on news of bankruptcy filingProactive Investors • 02/13/23
A biotech company that once claimed to have a 'cure' for COVID-19 just filed for bankruptcy, sending shares plunging 59%Business Insider • 02/13/23
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraineGlobeNewsWire • 02/12/23
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of StockholdersGlobeNewsWire • 02/05/23
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 02/04/23
Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 02/02/23
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 02/02/23
Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 01/30/23
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 01/30/23
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir BoostingGlobeNewsWire • 01/09/23
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 VirusGlobeNewsWire • 12/06/22
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)GlobeNewsWire • 12/05/22
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir BGlobeNewsWire • 11/29/22
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid ArthritisGlobeNewsWire • 11/13/22
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”GlobeNewsWire • 11/10/22
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business CombinationGlobeNewsWire • 11/10/22
Sorrento: Limited Potential, High Management Compensation, Complicated LawsuitsSeeking Alpha • 11/09/22
